HMGB1 and metabolic dysfunction-associated steatotic liver disease: These studies propose HMGB1 as a promising biomarker and potential therapeutic target of NAFLD and HBV-related HCC, but presently the epigenetic functions associated with HMGB1 in HCC remain unknown.